Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Relay Therapeutics, Inc. (RLAY) has a Wall Street consensus price target of $13.50, based on estimates from 14 covering analysts. With the stock currently trading at $10.26, this represents a potential upside of +31.6%. The company has a market capitalization of $1.78B.
Analyst price targets range from a low of $13.00 to a high of $14.00, representing a 7% spread in expectations. The median target of $13.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RLAY trades at a trailing P/E of -6.4x. Analysts expect EPS to grow +2.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RLAY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for RLAY is $13.5, representing 31.6% upside from the current price of $10.26. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RLAY has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $13.5 implies 31.6% upside from current levels.
RLAY's current price is $10.26 with a consensus target of $13.5 (31.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $14 for RLAY, while the most conservative target is $13. The consensus of $13.5 represents the median expectation. These targets typically reflect 12-month expectations.
RLAY is moderately covered, with 14 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 13 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RLAY stock forecast based on 14 Wall Street analysts shows a consensus price target of $13.5, with estimates ranging from $13 (bear case) to $14 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RLAY, with a "Buy" consensus rating and $13.5 price target (31.6% upside). 14 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RLAY analyst price targets range from $13 to $14, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13.5 consensus represents the middle ground.